Candel Therapeutics logo

Candel Therapeutics Share Price Today

(NASDAQ: CADL)

Candel Therapeutics share price is $8.14 & ₹707.93 as on 6 Mar 2025, 2.30 'hrs' IST

$8.14

0.26

(3.3%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Candel Therapeutics share price in Dollar and Rupees. Guide to invest in Candel Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Candel Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Candel Therapeutics share price movements

  • Today's Low: $7.73
    Today's High: $8.19

    Day's Volatility :5.62%

  • 52 Weeks Low: $1.34
    52 Weeks High: $14.60

    52 Weeks Volatility :90.82%

Candel Therapeutics (CADL) Returns

PeriodCandel Therapeutics IncIndex (Russel 2000)
3 Months
66.12%
0.0%
6 Months
24.88%
0.0%
1 Year
415.19%
0.0%
3 Years
97.0%
-11.6%

Candel Therapeutics (CADL) Key Statistics

in dollars & INR

Previous Close
$7.88
Open
$7.97
Today's High
$8.19
Today's Low
$7.73
Market Capitalization
$134.3M
Today's Volume
$175.9K
52 Week High
$14.6
52 Week Low
$1.34
Revenue TTM
$31.0K
EBITDA
$-34.7M
Earnings Per Share (EPS)
$-1.73
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-480.68%

How to invest in Candel Therapeutics Stock (CADL) from India?

It is very easy for Indian residents to invest directly in Candel Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Candel Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Candel Therapeutics or CADL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Candel Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Candel Therapeutics shares which would translate to 0.107 fractional shares of Candel Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Candel Therapeutics, in just a few clicks!

Returns in Candel Therapeutics (CADL) for Indian investors in Rupees

The Candel Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Candel Therapeutics investment value today

Current value as on today

₹5,20,139

Returns

₹4,20,139

(+420.14%)

Returns from Candel Therapeutics Stock

₹4,15,190 (+415.19%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Candel Therapeutics (CADL)

35%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Candel Therapeutics Stock from India on INDmoney has increased by 35% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Candel Therapeutics

  • FMR Inc

    8.82%

  • Baker Bros Advisors LP

    6.70%

  • Northpond Ventures, LLC

    4.35%

  • BRAIDWELL LP

    3.60%

  • Vanguard Group Inc

    3.01%

  • BlackRock Inc

    2.66%

Analyst Recommendation on Candel Therapeutics

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 7 Wall street analysts offering stock ratings for Candel Therapeutics(by analysts ranked 0 to 5 stars)

Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Candel Therapeutics Stock (CADL)

What analysts predicted

Upside of 35.14%

Target:

$11.00

Current:

$8.14

Insights on Candel Therapeutics Stock (Ticker Symbol: CADL)

  • Price Movement

    In the last 1 year, CADL stock has moved up by 398.7%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 31.0K → 1.77M (in $), with an average increase of 49.1% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -22.23M → -10.64M (in $), with an average increase of 108.9% per quarter

Candel Therapeutics Technicals Summary

Sell

Neutral

Buy

Candel Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Candel Therapeutics (CADL) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Candel Therapeutics Inc logo
4.23%
24.88%
415.19%
97.0%
16.29%
Regeneron Pharmaceuticals, Inc. logo
-3.09%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.43%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
0.82%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-10.36%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Candel Therapeutics Inc logo
NA
NA
NA
0.0
-4.81
-0.52
NA
0.44
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Candel Therapeutics Inc logo
Buy
$134.3M
16.29%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Organization
Candel Therapeutics
Employees
42
CEO
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Industry
Miscellaneous

Management People of Candel Therapeutics

NameTitle
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
President, CEO & Director
Dr. Francesca Barone M.D., Ph.D.
Chief Scientific Officer
Mr. Charles Schoch
Interim CFO, Principal Accounting Officer, Treasurer & Secretary
Dr. Seshu Tyagarajan Ph.D.
Chief Technical & Development Officer
Ms. Ileen B. Winick
Chief People Officer
Ms. Susan Stewart J.D., L.L.M.
Chief Regulatory Officer
Dr. William Garrett Nichols M.D., M.S.
Chief Medical Officer

Important FAQs about investing in CADL Stock from India :

What is Candel Therapeutics share price today?

Candel Therapeutics share price today stands at $8.14, Open: $7.97 ; Previous Close: $7.88 ; High: $8.19 ; Low: $7.73 ; 52 Week High: $14.60 ; 52 Week Low: $1.34.

The stock opens at $7.97, after a previous close of $7.88. The stock reached a daily high of $8.19 and a low of $7.73, with a 52-week high of $14.60 and a 52-week low of $1.34.

Can Indians buy Candel Therapeutics shares?

Yes, Indians can invest in the Candel Therapeutics (CADL) from India.

With INDmoney, you can buy Candel Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Candel Therapeutics at zero transaction cost.

How can I buy Candel Therapeutics shares from India?

It is very easy to buy Candel Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Candel Therapeutics (CADL) be purchased?

Yes, you can buy fractional shares of Candel Therapeutics with INDmoney app.

What are the documents required to start investing in Candel Therapeutics stocks?

To start investing in Candel Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Candel Therapeutics Stock (CADL)?

Today’s highest price of Candel Therapeutics (CADL) is $8.19.

Today’s lowest price of Candel Therapeutics (CADL) is $7.73.

What is today's market capitalisation of Candel Therapeutics?

Today's market capitalisation of Candel Therapeutics CADL is 134.3M

What is the 52 Week High and Low Range of Candel Therapeutics Stock (CADL)?

  • 52 Week High

    $14.60

  • 52 Week Low

    $1.34

What are the historical returns of Candel Therapeutics (CADL)?

  • 1 Month Returns

    4.23%

  • 3 Months Returns

    24.88%

  • 1 Year Returns

    415.19%

  • 5 Years Returns

    16.29%

Who is the Chief Executive Officer (CEO) of Candel Therapeutics ?

Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. is the current Chief Executive Officer (CEO) of Candel Therapeutics.